June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)
Author Affiliations & Notes
  • Yuichiro Ogura
    Department of Ophthalmology, Nagoya City Univ Medical School, Nagoya, Japan
  • Nicolas Feltgen
    Department of Ophthalmology,, University Hospital Göttingen, Göttingen, Germany
  • Jean-Francois Korobelnik
    Université de Bordeaux, Bordeaux, France
    INSERM (Institut National de la Santé Et de la Recherche Médicale), ISPED (Institut de Santé Publique d’Épidémiologie et de Développement), Bordeaux, France
  • Edoardo Midena
    University of Padova, Padova, Italy
  • Todd A Katz
    Bayer HealthCare Pharmaceuticals, Whippany, NJ
  • Claudia Teukmantel
    Bayer Pharma AG, Berlin, Germany
  • Carola Metzig
    Bayer Pharma AG, Berlin, Germany
  • Oliver Zeitz
    Bayer Pharma AG, Berlin, Germany
  • Footnotes
    Commercial Relationships Yuichiro Ogura, Bayer (C), Bayer (R); Nicolas Feltgen, Alimera (C), Allergan (C), Bayer (C), Novartis (C); Jean-Francois Korobelnik, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Roche (C), Thea (C), Zeiss (C); Edoardo Midena, Bayer (C); Todd Katz, Bayer (E); Claudia Teukmantel, Bayer (E); Carola Metzig, Bayer (E); Oliver Zeitz, Bayer (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1748. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuichiro Ogura, Nicolas Feltgen, Jean-Francois Korobelnik, Edoardo Midena, Todd A Katz, Claudia Teukmantel, Carola Metzig, Oliver Zeitz, ; Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1748.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The VIVID-DME and VISTA-DME clinical trials evaluated the efficacy and safety of IAI vs laser in patients with DME

Methods: Patients (N=872) were randomized to IAI 2mg every 4 weeks (2q4) + sham laser, IAI 2mg every 8 weeks (2q8) (after 5 initial monthly doses) + sham laser, or laser + sham injections. Primary endpoint was change from baseline in BCVA to Week 52 (W52). The current pooled VIVID-DME/VISTA-DME analysis examined outcomes at W52 in subgroups of baseline CRT <400µm or ≥400µm (by SD-OCT). The additional impact of baseline BCVA was also assessed within the 2 baseline CRT subgroups.

Results: Mean BCVA changes to W52 for IAI 2q4 and 2q8 vs laser were 10.2 and 10.0 vs 2.9 letters (CRT<400µm; P<0.0001), and 12.1 and 11.0 vs -0.1 letters (CRT≥400µm; P<0.0001). When patient subgroups were further categorized by both CRT and BCVA at baseline, IAI-treated patients consistently experienced greater improvements vs laser-treated patients. In the subgroup with greatest baseline impairment (CRT≥400µm + BCVA<40 letters; n=63), mean BCVA changes for 2q4 and 2q8 vs laser were 18.2 and 18.3 vs -0.6 letters; in the subgroup with least baseline impairment (CRT<400µm + BCVA≥65; n=134), a group not expected to show substantial improvements, mean BCVA changes were +9.5 and +7.6 vs +2.3 letters. Mean changes in CRT to W52 for 2q4 and 2q8 vs laser were -68.7 and -77.9 vs 0.8µm (CRT<400µm; P<0.0001), and -244.2 and -228.6 vs -96.5µm (CRT≥400µm; P<0.0001). Proportions of patients with a ≥2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) to W52 were 31.9% and 29.5% vs 15.0% (CRT<400µm; P≤0.05), and 37.0% and 30.2% vs 11.9% (CRT≥400µm; P<0.01). Cataract (VIVID-DME) and vitreous haemorrhage (VISTA-DME) were the most common ocular SAEs in study eyes treated with IAI (both 2 patients [0.7%]).

Conclusions: These results suggest that the visual, anatomical and DRSS benefits of IAI 2q4 and 2q8 over laser are robust and similar in patient subgroups based on CRT and BCVA at baseline. Moreover, visual benefits appear to be greater with IAI regardless of both CRT and BCVA at baseline. Consistent benefits on the DRSS indicate an effect of IAI not only on DME, but also on the underlying diabetic retinopathy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×